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Summary
Objectives: The objective of this study was to evaluate the oral combination of glucosamine HCl, sodium chondroitin sulfate and manganese
ascorbate for the treatment of osteoarthritis (OA) of the knee.
Design: A randomized placebo-controlled study design was implemented. We recruited 93 patients with OA of the knee from a single center.
The intervention group received 1000 mg FCHG49Y glucosamine HCl, 800 mg TRH122Y low molecular weight sodium chondroitin sulfate
and 152 mg manganese ascorbate twice daily (Cosamin®DS). Patients were evaluated initially and then every 2 months for 6 months. The
primary outcome was the Lesquene Index of severity of osteoarthritis of the knee (ISK).
Results: Patients with radiographically mild or moderate OA (N=72) in the intervention group showed significant improvement in the ISK at
4 and 6 months (P=0.003 and P=0.04, respectively). The response rate to the medication was 52% vs a 28% response rate to placebo.
Patients with radiographically severe osteoarthritis (N=21) did not show significant improvements in the ISK. There was a 17% incidence of
adverse events in the intervention group and 19% in the placebo group.
Conclusions: The studied combination of glucosamine HCl, sodium chondroitin sulfate and manganese ascorbate was found to be effective
for the treatment of radiographically mild to moderate OA of the knee as measured by the ISK. This is the first U.S. study of these agents.
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The current medical management of osteoarthritis (OA) is
largely palliative, focusing on the amelioration of pain and
the suppression of inflammation, mostly through analgesics
and nonsteroidal anti-inflammatory drugs (NSAIDS).1
NSAIDS do not improve the natural history of the disease.
In fact, Dr Kenneth Brandt, in an article entitled ‘Should
NSAIDs be used for the treatment of osteoarthritis?’,
summarized data suggesting that some NSAIDs might
even accelerate the degenerative process of OA because
they might decrease glycosaminoglycan (GAG) synthesis.2
These perplexities regarding the long-term use of NSAIDs,
along with expanding knowledge on cartilage biochemistry
and OA pathophysiology, have prompted research on a
series of new agents that are being studied for their
specific effects on this disease. Chondroitin sulfate and
glucosamine are two of these agents.
Glucosamine is an amino-monosaccharide derived from
chitin in crustacean shells. Studies indicated that glu-343cosamine stimulates the synthesis of proteoglycans5–7 as
well as possessing anti-inflammatory activity in different
animal models without inhibiting the synthesis of prosta-
glandins.3,4 Glucosamine exhibited no known toxicity at
doses far in excess of those used in human clinical trials,
as might be expected from a naturally-occurring substance.
Compared to indomethacin, the therapeutic margin with
regard to prolonged treatment is 10–30 times more favora-
ble for glucosamine.4 Chondroitin sulfate extracted from
bovine trachea is a long-chain polymer of repeating disac-
charide units: galactosamine sulfate and glucuronic acid,
and constitutes the majority of GAGs in articular cartilage.
The proposed mechanisms of action of chondroitin sulfate
in OA are: (1) contribution to the pool of GAGs in cartilagi-
nous tissue; (2) inhibition of synovial degradative enzymes;
and (3) stimulation of GAGs and collagen synthesis by
chondrocytes.6–9 The studied combination also contained
manganese which is a cofactor necessary for the efficient
synthesis of proteoglycans.10 In order for these substances
to be effective when given orally, they must be absorbed
and reach the site where they work. Radiolabeled glu-
cosamine given orally to six human volunteers was 90%
absorbed.11 Necropsy of dogs given oral radiolabeled glu-
cosamine showed that glucosamine had a tropism for
articular cartilage.12 Radiolabeled chondroitin sulfate given
orally to humans was also 70% absorbed.13 Its affinity for
synovial fluid and articular cartilage has also been demon-
strated.13 In vitro,5,7–9,14 and in vivo15–17 data suggest that
these compounds may positively alter the natural history of
OA.
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clinical data on these agents, there are copious data
available from the European literature on glucosamine24–37
and on chondroitin sulfate.15,16,37–43 Only a small number
of the previous studies had a randomized, double-blind,
controlled design and studied only a single joint (such as
the knee) and used a validated outcomes tool (such as the
Lesquene index of severity of osteoarthritis of the knee,
ISK). Muller-Fassbender et al.32 conducted a clinical trial of
oral glucosamine and found it to be equally efficacious to
ibuprofen in the treatment of OA of the knee. Ibuprofen
worked more quickly than glucosamine but also had more
side effects. Noack et al.33 found that patients with OA of
the knee on oral glucosamine had a decrease in the ISK
significantly more than placebo. Response to the medi-
cation was defined as a drop in the ISK of 3 points and 52%
of patients responded to glucosamine compared to 37% of
patients responding to placebo (P=0.016). In a study of
oral chondroitin sulfate for treatment of OA of the knee,
Mazieres et al.40 noted a significant drop of 3 points the ISK
score in the intervention group compared to 1.5 points drop
in the placebo group (P<0.02). Several other clinical
studies confirmed its efficacy in OA patients.15,16,37–43
It has been postulated that combining glucosamine with
chondroitin sulfate yields a synergistic rather than addi-
tive effect45–47 because glycosaminoglycan production is
stimulated by glucosamine and degradation is inhibited by
chondroitin sulfate. This theory was supported in a recent
study that showed that a combination of glucosamine and
chondroitin was synergistic, having significantly higher
effect than the additive effects of the individual ingredi-
ents.22 The purpose of this study was to evaluate the
effectiveness of the studied combination of agents in
the treatment of the symptoms of OA of the knee. This
study did not address the question of whether or not
they are disease-modifying agents nor did it assess the
synergistic effect between the individual components.Materials and methods
All patients were recruited from the principal investi-
gator’s orthopedic practice in Hendersonville, NC. Eight
hundred and twenty-three patients responded to an article
in the local newspaper on the intended study. These were a
mix of osteoarthritic patients and ‘self diagnosed’ ones, so
patients were first screened by mail using the criteria listed
below.EXCLUSION CRITERIA
These criteria included pregnancy, severe activity-
limiting chronic diseases, non-insulin-dependent diabetes,
alcoholism, history of significant hematological disorder,
history of hepatic or renal impairment, active peptic ulcer,
associated musculoskeletal disease other than OA, associ-
ated metabolic diseases, injury to or surgery on the
involved knee within 6 months, intraarticular cortico-
steroids within the previous 2 months and regular use
(more than three times a week) of NSAIDs during the
previous 2 months. The occasional use of NSAIDs as
rescue medication was accepted. Patients using NSAIDs
regularly were given a 2-week trial period to use NSAIDs as
a rescue medication before being admitted to the study.INCLUSION CRITERIA
Patients not exhibiting any of the exclusion criteria were
then evaluated using the Lesquene index of severity ofosteoarthritis of the knee (ISK).21 Patients with an ISK of at
least 7 points were then evaluated radiographically. Weight
bearing posteroanterior radiographs at 45° flexion were
obtained for every patient by the same technician using a
jig, which is a mechanical device used for consistent
positioning of the patient. It assures 45° of flexion and
centering of the knees on the X-ray film.18 Radiographs
were assessed jointly by the principle investigator and a
board certified radiologist using the Kellgren and Lawrence
atlas.19,20 Individuals with grade 2 or more were eligible for
the study. The reader will recall that Kellgren and Lawrence
defined radiographic grades of osteoarthritis as grade
0=normal; grade 1=doubtful narrowing of joint space and
possible osteophytic lipping; grade 2 (mild)=definite osteo-
phytes and possible narrowing of joint space; grade 3
(moderate)=moderate multiple osteophytes, definite nar-
rowing of joint space, some sclerosis, and possible
deformity of bone contour; and grade 4 (severe)=large
osteophytes, marked narrowing of joint space, severe
sclerosis and definite deformity of bone contour. Further
inclusion criteria were as follows: both genders between 45
and 75 years of age, ability to walk, willingness to comply
with the study protocol and arthritic symptoms of greater
than 6 months duration. Patients meeting the above criteria
were then accepted into the study and included in the intent
to treat analysis after they had their baseline visit. Patients
with both unilateral and bilateral OA were accepted. In
patients with bilateral involvement, only the more sympto-
matic knee was studied. Ninety-three patients were
accepted into the study. The primary goal of the study was
to assess patients with Kellgren and Lawrence radiological
grades 2 and 3. However, a surprising number of patients
with grade 4 OA presented for the study. Since no other
study had accepted or at least separately evaluated grade
4, it was elected post hoc to accept these patients to
evaluate them separately.
Patients were allocated to the intervention (N=46) and
placebo (N=47) groups using a randomized block design.
The group assignment was generated before the start
of patient recruitment. The randomization schedule was
obtained using a computer-based pseudo-random number
generator. Each bottle was given a sequential number
(1,2,3, . . .) with the code concealed to the investigator. The
sequential numbers were matched with the order of inclu-
sion of eligible patients into the study. Neither the patient
nor the evaluating physician was aware of the treatment
assignment. After termination of the study, letters were sent
to the principle investigator (Dr Das) with the treatment
assignment in order to inform the patients. Compliance was
measured by pill counts carried out by the interviewer at
every visit.
Of the 46 patients randomized to the intervention group
33 had Kellgren and Lawrence grade 2 or 3 OA and 13 had
Kellgren and Lawrence grade 4 OA. Of the 47 patients
randomized to the placebo group 39 had Kellgren and
Lawrence grade 2 or 3 OA and 8 had Kellgren and
Lawrence grade 4 OA. Patients received two capsules
twice a day orally. Each intervention capsule contained
500 mg FCHG49Y glucosamine hydrochloride, 400 mg
TRH122Y low molecular weight sodium chondroitin sul-
fate, and 76 mg manganese ascorbate (Cosamin®DS,
Nutramax Laboratories Inc., Baltimore, MD, U.S.A.). The
glucosamine hydrochloride and sodium chondroitin sulfate
were assayed by the School of Pharmacy at University of
Maryland at 99% and 95% purity, respectively. The placebo
group received indistinguishable capsules containing
methyl-cellulose. Patients were evaluated initially and then
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administered instruments were used to assess the effec-
tiveness of the studied combination of agents: the
Lesquene index of severity of osteoarthritis of the knee
(ISK)21 and the visual analog version of the Western
Ontario and McMaster Universities osteoarthritis index
(WOMAC).23 The primary outcome was the ISK because it
was used by most of the previous studies on glucosamine
or chondroitin sulfate. The same interviewer was used for
all patients and for every visit. Patients were examined by
the principal investigator at every visit. At each visit,
patients were asked to make a global self-assessment of
their OA on a visual analog scale. When administering ISK,
WOMAC, and patient’s global assessment, patients were
instructed to consider their condition over the previous 2
weeks (vs how they felt on the day of the examination).21,23
A daily diary of patients’ use of rescue pain medications
was kept by the patient. They were allowed to use over-
the-counter NSAIDs and acetaminophen. Use of rescue
medication greater than 3 days per week was discouraged.
Information was also collected on the rate, duration and
severity of adverse events.
The study was approved by the Margaret R. Pardee
Memorial Hospital Institutional Review Board and was
conducted in accordance with the World Medical
Association’s Helsinki Declaration of 1975, as revised in
1983. An informed consent containing details of the study
was provided to patients prior to enrollment. All patients’
information was kept confidential.Statistical analysis
The sample size was calculated to achieve a study
power of 80%. This was based on a difference of two points
or more between the intervention and placebo in the
primary outcome (ISK score), with a standard deviation of
3.0 or less. The WOMAC score was collected as a second-
ary outcome for comparative purposes. Missing data for
patients were imputed using the data of the last recorded
visit as a conservative estimate. The ‘intention-to-treat’
concept was implemented. In other words, persons
assigned to either intervention or placebo groups wereanalysed as such irrespective of their compliance. All
patients that had a baseline visit and received their
medications were included in the analysis.
Several characteristics of the patient population were
analysed. A statistical comparison of these characteristics
was carried out to verify the comparability of the interven-
tion and the placebo groups. These characteristics are
listed in Table I. Repeated measurement analysis was done
using SAS® (Statistical Analysis System, Cary, NC), PROC
MIXED®. We employed a linear model with fixed effect
terms for baseline score, treatment group, time and the
group by time interaction. As part of the analysis, we
computed differences between treatment groups at 2
months, 4 months and 6 months, adjusting for any baseline
differences, and tested the significance between groups.
Due to the heterogeneity of variances among time points,
an unspecified covariance structure was used throughout.
All P-values reflect between-group comparison. Analysis
was planned a priori to be stratified by the radiographic
severity of OA, with the mild/moderate severity as the
primary study population.
Other data in the form of counts were statistically ana-
lysed using chi-square tests for contingency tables. A
positive response to the studied compounds was defined
as improvement of 25% or more in the various parameters
studied (ISK, WOMAC or patients global assessment).
Quantitative data, for baseline differences, were analysed
using two-sample t-test. Pearson correlation coefficient
was calculated to test the association between the changes
in the ISK score, the WOMAC score, and the patient’s
global assessment. Dr Murray Selwyn, with the ‘Statistics
Unlimited, Inc.’, performed the primary statistical analysis
and no interim analysis was scheduled.Table I
Demographics and characteristics of study patients (N=93)
Placebo
(N=47)
Intervention
(N=46)
P-value
Age (years)* 66.0 (±1.5) 64.5 (±9.8) 0.5
Body mass index* 30.2 (±0.9) 30.5 (±1.0) 0.8
Male gender 10 (22%) 13 (28%) 0.4
Married 34 (72%) 38 (83%) 0.2
Season of recruitment in study
—Fall 11 (23%) 10 (22%)
—Winter 13 (28%) 16 (35%)
—Spring 14 (30%) 13 (28%)
—Summer 9 (19%) 7 (15%) 0.9
OA in other joints 21 (45%) 15 (33%) 0.2
Secondary OA 6 (13%) 7 (15%) 0.7
Severe OA 8 (17%) 13 (28%) 0.2
Weight change from baseline (lb)* 0 (±1.2) −0.7 (±0.9) 0.8
Duration of OA in study-joint (years)* 7.4 (±1.2) 5.6 (±1.3) 0.3
Mean follow-up period (months)* 6.5 (±0.1) 6.4 (±0.1) 0.6
OA=osteoarthritis.
*Data presented are means (±standard errors).Results
Demographics and characteristics of study patients at
baseline are presented in Table I, showing no significant
difference between the placebo and the intervention
groups, verifying the comparability of the two groups.
Among the 93 patients, 72 (77%) had radiographically
mild or moderate OA (Kellgren and Lawrence radiographic
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Mean (±standard error) and percent change from baseline of clinical findings over the study period among study patients stratified by
radiographic severity
Visit Mild/moderate cases (N=72) Severe cases (N=21)
Placebo (N=39) Intervention (N=33) Placebo (N=8) Intervention (N=13)
Lequesne ISK Baseline 10.4 (±0.4) 10.2 (±0.4) 10.7 (±1.2) 11.1 (±0.8)
At 2 months 9.6 (±0.5) 8.9 (±0.5) 10.1 (±1.4) 10.2 (±0.8)
At 4 months 9.2 (±0.6) 7.2 (±0.6)* 9.6 (±1.5) 9.4 (±0.9)
At 6 months 9.0 (±0.6) 7.4 (±0.6)† 9.9 (±1.6) 9.6 (±1.0)
>=25% improvement 11 (28%) 17 (52%)‡ 2 (25%) 3 (23%)
WOMAC Baseline 944 (±55) 908 (±71) 1089 (±158) 1187 (±119)
At 2 months 831 (±64) 768 (±71) 984 (±166) 1134 (±121)
At 4 months 774 (±79) 655 (±72) 900 (±174) 1041 (±126)
At 6 months 724 (±87) 626 (±77) 882 (±183) 1033 (±126)
>=25% improvement 16 (41%) 19 (58%) 2 (25%) 4 (31%)
Patient’s global Baseline 49.4 (±3.4) 48.9 (±4.0) 60.4 (±6.6) 54.0 (±3.9)
Assessment At 2 months 40.5 (±3.4) 39.0 (±3.7) 53.0 (±5.5) 50.1 (±4.5)
At 4 months 38.4 (±4.0) 31.4 (±3.8) 47.4 (±5.9) 46.5 (±5.1)
At 6 months 36.1 (±4.5) 30.8 (±4.1) 43.9 (±8.2) 45.2 (±4.9)
>=25% improvement 18 (46%) 23 (70%)§ 3 (38%) 4 (31%)
*P=0.003, †P=0.04, ‡P=0.04, §P=0.04. These P values represent the significant differences between the changes in the intervention and
the control groups.Table III
Adverse events in the placebo and the intervention groups
Events Placebo
(N=47)
Intervention
(N=46)
GI upset (constipation, indigestion, gas) 10 (21%) 7 (15%)
Bad taste 3 (6%) 1 (2%)
Fatigue — 1 (2%)
Diabetes (type II) — 1 (2%)
Hypothyroidism — 1 (2%)
Muscle cramps 1 (2%) —
Phlebitis 1 (2%) —
Total number of patients* 9 (19%) 8 (17%)
*The total number of patients does not match the numbers
mentioned in the individual cells in the table because some
patients reported more than one adverse event.grades 2 and 3) and 21 (23%) had severe OA (grade 4).
The results are presented in Table II. The ISK in the
radiographically mild or moderate group was 10.4 (±0.4) in
patients receiving placebo at baseline and 10.2 (±0.4)
in patients receiving the intervention. By 4 months the ISK
had dropped to only 9.2 (±0.6) in the placebo group but
went down to 7.2 (±0.6) in the intervention group. The
difference in the ISK was highly significant (P=0.003). At
six months the difference in the ISK of the mild or moderate
placebo group vs the intervention group was also signifi-
cant (P=0.04). A significant difference was not noted at two
months (P=0.2). Although a similar trend of improvement
was observed, the results were not significant when
measured by the WOMAC score (P=0.5) or by the patient’s
global assessment (P=0.4). The Pearson correlation coef-
ficients (R) between the changes in OA symptoms
measured by various instruments were as follows: ISK/
WOMAC R=0.56, P=0.001; ISK/global patient’s assess-
ment R=0.36, P=0.0003; and WOMAC/global patient’s
assessment R=0.63, P=0.0001.
For purposes of this study, response to the treatment
was defined as a 25% improvement in the parameter
studied (ISK, WOMAC or patient’s global assessment),
with the ISK as the primary outcome. The results are
presented in Table II. In the radiographically mild/moderate
subgroup of patients, the ISK showed that 52% of the
intervention group responded vs 28% of the placebo group
(P=0.04). When the WOMAC was used to evaluate the
results 58% of the intervention group responded vs 41% of
the placebo group (P=0.2). When the patients’ global
assessments were used to evaluate the results 70% of the
intervention group responded vs 46% of the placebo group
(P=0.04).
With the numbers available (N=21), there were no
significant differences in the response of the intervention vs
placebo groups of patients with radiographically severe
arthritis whether the results were measured with the ISK,
WOMAC or patients’ global assessments.
The drop in the use of rescue pain medications, from
two months in the study to six months, by 50% or
more, approached but did not achieve significance in themild/moderate subgroup (19% and 39% in the placebo
and intervention groups, respectively, P=0.08). It also
approached but did not achieve significance in the severe
subgroup (0% and 31% in the placebo and intervention
groups, respectively, P=0.1).
Adverse events are presented in Table III. There was a
19% incidence of adverse events among the placebo group
and a 17% incidence of adverse events among the inter-
vention group. The majority of these events were transient.
One patient dropped out in both the placebo and inter-
vention groups because of gastrointestinal upset. Another
patient in the placebo group dropped out for knee joint
replacement surgery. A third patient in the placebo group
dropped out because of intolerable pain requiring intra-
articular steroid injection. Thus, only four patients (4%)
dropped out of the study.
Reasons for missing data were as follows (out of 372
total visits): major change in physical activities (one visit,
0.3%), 50% or more of the follow-up period taking pain
medications (three visits, 0.8%), patients dropped out (nine
visits, 2.4%), co-morbidity not related to the study medi-
cation and accidents (six visits, 1.6%), steroid admin-
istration (12 visits, 3.2%), study termination (seven visits,
Osteoarthritis and Cartilage Vol. 8 No. 5 3471.9%), unacceptable time lapse between visits (24, 6.5%).
Acceptable time limits were 49–77 days between visits or a
total study period of 147–210 days. Thus, 16.6% (62/372)
of the data was modified as described under statistical
analysis.Discussion
We presented the first clinical trial of the combination of
glucosamine hydrochloride, sodium chondroitin sulfate and
manganese ascorbate in the management of knee OA. In
this study a significant improvement in OA symptoms was
observed. The results are in agreement with previous
reports on osteoarthritic animals49–52 and humans62 study-
ing the same combination of glucosamine, chondroitin
sulfate and manganese ascorbate. In one of these studies,
Leffler et al.61 studied middle-aged athletic population suf-
fering from knee and back OA and reported significant
symptomatic improvement.
Most of the studies of either glucosamine or chondroitin
sulfate have used the ISK score as their primary outcome
showing similar magnitude of improvement to the current
study. According to Lequesne et al.,53 it is expected in the
assessment of a new intervention to find an initial score of
8–12 points by ISK score and to find an average decrease
of three points after starting the intervention. The fact that
patients in the radiographically severe group did not
improve, with the available number, is not surprising since
the proposed mechanism of action is dependent on the
existence of cartilage in the arthritic joint. Most previous
clinical trials on the individual agents did not include, or did
not report separately, this group of patients in their study
population. It is worthwhile to note that there are a small
number of patients in the radiographically severe group
in our study. Thus, a definitive statement regarding the
efficacy in this group of patients cannot be made.
Although the efficacy in the mild to moderate group was
significant as reflected in the change of the ISK score, the
WOMAC score did not achieve statistical significance. We
used the visual analog version of the WOMAC index. It is
possible that in the case of studies spanning several
months, using agents that exhibit subtle improvement
might result in more variability because patients have more
difficulty deciding on the level of their symptoms with the
visual analog. To the authors’ knowledge, the only pub-
lished study that used WOMAC index in assessing a slow
acting agent in the treatment of OA was by Houpt et al.68
Despite a positive trend, the results were not statistically
significant because of the high variation in the WOMAC
index.
The correlations between the ISK and WOMAC scores
were ‘statistically’ significant. Nevertheless, the correlation
coefficients are not impressively high, which is in concord-
ance with a previous report by Bellamy et al.23 Notice also
that the correlation between the change in WOMAC score
and patient’s global assessment is higher than between
either of them and the change in the ISK score, which might
be a function of the order of administration of question-
naires. A comprehensive assessment of validity has been
reported for both the ISK and the WOMAC scores. How-
ever, they were introduced with different specific concepts
of measurement.20 The limited accordance of ISK and
WOMAC scores should not be regarded as evidence
against their usefulness in clinical studies, but as an
indication that these two scores measure slightly different
aspects of the same disease. For example, in painmeasurement, the ISK score measures mainly the type
of pain while the WOMAC score measures the severity of
pain.20
Interestingly, the studied combination contained
manganese. The rationale behind its use is that
manganese storage in the body is minimal.62 However,
while dietary manganese overload appears to be non-
existent, it is estimated that 37% of the American popu-
lation has low manganese intake.63 Occult manganese
deficiency appears to be a likely factor in bone loss
and degenerative joint conditions for even well-fed
Americans.64 Manganese salts have superoxide
dismutase-like activity which is dose related,65 and is a
co-factor for mitochondrial superoxide dismutase62 which
inhibits oxidative damage in tissues.65 Furthermore,
manganese is an essential trace element that has a role in
GAG synthesis and in activating glycosyltransferase
enzymes that attach modified sugars to proteins (collagen)
and to each other.10 To date, manganese toxicity due
excessive dietary intake alone has not been firmly identi-
fied in humans.66 The level of oral intake of manganese
associated with adverse effects is debatable reflecting a
number of factors influencing manganese retention, such
as past manganese intake and iron, calcium, phos-
phorus and phytate in the diet.67 Nevertheless, caution is
warranted in this area and high intake of manganese is not
recommended.66
With the publicity given to the studied agents, the public
at large is extensively self-medicating. Since these sub-
stances are available over the counter under a number of
different labels, there is unfortunately no guarantee that the
quality of glucosamine and chondroitin sulfate they receive
is satisfactory. Hungerford47 draws attention to the fact that
glucosamine and chondroitin sulfate are both obtained from
animal tissue sources and purity can vary widely depending
on extraction techniques and analysis technology. Most
previous studies on glucosamine and chondroitin sulfate,
and certainly the current study, were conducted using
carefully assayed, purified compounds. The purity and
molecular weight of the compounds used can certainly be
expected to affect bioavailability and consequently efficacy.
Glucosamine and chondroitin sulfate are considered
dietary supplements in the U.S.A., rather than drugs.
Therefore, the Food and Drug Administration does not
regulate their manufacturing. Although many brands of
glucosamine and chondroitin sulfate are available over the
counter, independent laboratory analyses have shown that
many products do not actually contain the amounts or
purity claimed on the label.48 It would be logical to recom-
mend that manufacturers use self-imposed quality-control
programs and pharmaceutical-type good manufacturing
practices (GMPs) until the FDA regulates the industry. A
similar concern was voiced in a recent editorial in the New
England Journal of Medicine.55
There was no significant difference in the rate of adverse
events between the intervention and the placebo groups.
One patient in the intervention group was diagnosed with
type II diabetes mellitus during the study. Intravenous
glucosamine has been shown to result in hyperglycemia in
experimental animals.56–58 However, these studies loaded
the animals with large doses of glucosamine given in a very
short period. A safety study of oral administration of the
same combination in animals did not report elevation of
blood glucose.49 Furthermore, no significant elevation in
blood glucose was reported by previous clinical trials.33,62
The authors did not have baseline blood studies and were
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studies are warranted.
Agents such as glucosamine have been proposed in the
XVIIIth International League Against Rheumatism (ILAR)
Congress of Rheumatology as slow acting agents in OA
based on its pharmacological and clinical profile.45 Thus,
such agents have an entirely different mechanism of action
from other available medications. The studied combination
of agents has potential for being a disease modifying
osteoarthritis drug (DMOAD) based on previous in vitro,15
in vivo,59–61 and clinical16,17 studies. They are postulated
to slow the degenerative process of osteoarthritis. As of
now, there is no established DMOAD available. DMOADs
have the potential to provide yet another tool in the arma-
mentaria against OA, the leading cause of joint replace-
ment. The potential impact of DMOADs on the field of
joint replacement is profound. Extending the interval
between diagnosis and surgical intervention, thus post-
poning joint replacement, would be especially beneficial for
younger patients facing the possibility of more than one
replacement in their lifetime. Our study did not address the
question of whether or not these agents are DMOADs.
Long-term studies are warranted to further investigate this
possibility.
In conclusion, the studied combination* of glucosamide
hydrochloride, sodium chondroitin sulfate and manganese
ascorbate is effective in the management of osteoarthritis
of the knee. They have no known serious side-effects.Acknowledgments
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